Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

@article{Bergeron2003IronCP,
  title={Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.},
  author={Raymond J. Bergeron and Jan Wiegand and William R. Weimar and James S. McManis and Richard E. Smith and Khalil A Abboud},
  journal={Chirality},
  year={2003},
  volume={15 7},
  pages={593-9}
}
For patients who require lifelong blood transfusions, there is no efficient means, unless chelation therapy is employed, for elimination of excess iron. Alternatives to desferrioxamine, the currently accepted treatment for transfusional iron overload, are being investigated. The current article focuses on an enantiomeric pair of analogs of desferrithiocin, (+)-(S)- and (-)-(R)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylic acid (4'-hydroxydesazadesferrithiocin). The crystal… CONTINUE READING